01.13.21

Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study

Source: Glaukos

02.11.20

Ocular Therapeutix Presents Data Demonstrating a Reduction in IOP in Patients Treated with OTX-TIC

Source: Ocular Therapeutix

05.03.18

Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC for the Treatment of Glaucoma

Source: Ocular Therapeutix

View more stories